CFTR and cystic fibrosis: New CFTRm therapies have been available with reimbursement in Finland since early 2021: 1) the combination of lumacaftor and ivacaftor (Orkambi®) for people aged ≥2 years with CF who are homozygous for F508del-CFTR (F/F genotype); 2) the combination of tezacaftor and ivacaftor (Symkevi®) for people aged ≥6 years with CF who have the F/F genotype or are heterozygous for F508del-CFTR and a residual function mutation; and 3) the triple combination of elexacaftor, tezacaftor, and ivacaftor (Kaftrio®) for people aged ≥6 years with CF with ≥1 copy of F508del-CFTR [[8], [9], [10], [11]].